Business
PDS updates on Versamune based COVID-19 vaccine
PDS updates on Versamune based COVID-19 vaccine.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0210F\n NetScientific PLC\n 11 November 2020\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\" or the \"Company\")\n \n PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine\n \n PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency\n \n \n London, UK - 11 November 2020 - NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation (\"PDS\") (Nasdaq: PDSB) announced progress on its co-development program with Farmacore Biotechnology for a Versamune®-based vaccine aimed at preventing COVID-19 infection.\n Based on promising and robust preclinical data with PDS0203, and in the interest of rapid development, PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune®-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins. The decision to jointly develop PDS0203 was made with the support of the Agência Nacional de Vigilância Sanitária (ANVISA) following a successful pre-investigational new drug meeting on November 06, 2020. ANVISA and Farmacore reviewed the PDS0203 data and agreed on the path forward for official submission of a final data package and the phase 1/2 human clinical trial protocol. Farmacore is in discussions with specific agencies of the government to extend the preclinical funding to cover the upcoming human clinical trial anticipated to begin during the first half of 2021.\n \n \"PDS0203 may present strong potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19,\" said Dr. Greg Conn, Chief Scientific Officer of PDS Biotechnology.\n \n \"PDS Biotech and Farmacore are now one step closer to advancing our Versamune®-based COVID-19 vaccine into the clinic,\" said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. \"The preclinical results of PDS0203 demonstrate its potential to induce a robust and broad immune response. We look forward to evaluating our next-generatio...